All questions
Safety: Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer 9 questions · 3 sources
Safety questions that apply to every indication of Ibrance are on Ibrance (palbociclib), all indications: Safety .
Side effects What are the most common side effects of Ibrance with letrozole (PALOMA-2)? Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
“The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).” (opens the source at this quote in a new tab) Copy Flag
What are the most common side effects of Ibrance with fulvestrant (PALOMA-3)? Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
“The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%).” (opens the source at this quote in a new tab) Copy Flag
What blood test abnormalities occur with Ibrance (PALOMA-2 and PALOMA-3)? Does Ibrance cause nosebleeds, dry eye, or blurred vision? How often did side effects lead to stopping Ibrance (PALOMA-2, PALOMA-3)? Warnings How common is neutropenia (low neutrophil count) with Ibrance? Can Ibrance cause lung problems (ILD or pneumonitis)? Safety management How often did neutropenia lead to Ibrance dose changes (PALOMA-2, PALOMA-3)? Was G-CSF allowed for neutropenia in the Ibrance PALOMA-2 and PALOMA-3 trials?